Subtype
Digestive System Neuroendocrine Tumor
CI-CAN-00000823Explore in graph →
Non-malignant62 active trials1 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000823Explore in graph →
Clinical trials
256 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01824875 | Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 144 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors(STELLAR-311) | recruiting | Phase 2 / Phase 3 | 440 | ExelixisINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT00001276 | Diagnosing and Treating Low Blood Sugar Levels | recruiting | — | 1,500 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05196087 | Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)(NIP IT!) | recruiting | — | 800 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05773274 | Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial | recruiting | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 2 | Sep 24, 2026 | clinicaltrials |
| NCT03967951 | CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms | completed | — | 70 | Francesco De CobelliOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | active not recruiting | Phase 3 | 298 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07817225 | Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation(ORACLE) | active not recruiting | — | 30 | Massimo FalconiOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen(CAREFNDR) | recruiting | Phase 3 | 141 | Crinetics Pharmaceuticals Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT07165132 | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | recruiting | Phase 1 | 104 | RayzeBio, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06784752 | Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET(NETTER-3) | recruiting | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 11, 2026 | clinicaltrials |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | active not recruiting | Phase 1 | 152 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07808879 | Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization(HBED-CC-PEG6-E) | recruiting | N/A | 20 | Peking Union Medical College HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06725693 | Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease | recruiting | — | 500 | Tianjin Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05687123 | Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors | recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 2 | Sep 3, 2026 | clinicaltrials |
| NCT05247905 | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial | active not recruiting | Phase 2 | 31 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT00569127 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | active not recruiting | Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT01841736 | Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | active not recruiting | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT05997056 | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | completed | Phase 2 | 12 | Aadi Bioscience, Inc.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05064150 | Neuroendocrine Tumors - Patient Reported Outcomes(NET-PRO) | active not recruiting | — | 2,539 | University of IowaOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07274657 | Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy(SMILE) | recruiting | N/A | 150 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06427798 | Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | recruiting | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04609592 | Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | active not recruiting | Phase 1 | 10 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07759960 | Underwater Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Small Rectal Neuroendocrine Tumors | recruiting | N/A | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04993261 | An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | active not recruiting | Early Phase 1 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05262556 | NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas | completed | Phase 1 | 15 | Amr Mohamed MDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06876532 | Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour(LUTIBI) | recruiting | N/A | 150 | Institut Claudius RegaudOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07695532 | A Clinical Risk Score to Stratify High-risk PanNETs | completed | — | 552 | Fudan UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07635316 | A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | recruiting | — | 4,023 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06016855 | Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 4 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06091748 | Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors | completed | Phase 3 | 69 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06158516 | A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 6 | Changhai HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07612748 | Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms | recruiting | N/A | 483 | Jilin UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07619417 | Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms | not yet recruiting | N/A | 12 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05884255 | An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. | recruiting | Phase 3 | 220 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07591493 | Adjuvant Trial in Pancreatic Neuroendocrine Tumors(ADJUPANET) | not yet recruiting | Phase 3 | 300 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05636618 | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors | recruiting | Phase 1 / Phase 2 | 300 | Perspective TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT05988918 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | active not recruiting | Phase 2 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03583528 | DOTATOC PET/CT for Imaging NET Patients | active not recruiting | — | 800 | British Columbia Cancer AgencyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07554560 | Nutrition Intervention for Pancreatic Cancer | recruiting | N/A | 18 | Children's Hospital of PhiladelphiaOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04727723 | Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs(REAL-LU) | completed | — | 164 | Novartis PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT01916148 | 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia | available | — | — | Children's Hospital of PhiladelphiaOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07165886 | Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 2 / Phase 3 | 298 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07536087 | Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors | recruiting | N/A | 50 | Institute for Clinical and Experimental MedicineOTHER_GOV | 1 | Apr 17, 2026 | clinicaltrials |
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials